FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database Award winning LMD collection will be fully integrated into FDNA's Face2Gene dysmorphology search and reference solution


FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database

Award winning LMD collection will be fully integrated into FDNA's Face2Gene dysmorphology search and reference solution

PR Newswire

NEW YORK and LONDON, August 26, 2014 /PRNewswire/ --


 

FDNA Inc. (http://www.fdna.com) and London Medical Databases Ltd. (http://www.lmdatabases.com) announced today that they have partnered to offer, for the first time, online access to the award winning database exclusively through FDNA's solutions.

FDNA, developer of the Facial Dysmorphology Novel Analysis technology, will fully integrate LMD's award-winning collection into Face2Gene[ TM ], the only available dysmorphology genetic search and reference solution, using facial analysis technology. Combining the power of Face2Gene's advanced facial dysmorphology analysis and phenotype search algorithms and of LMD's comprehensive collection of images and medical reference into one, simple to use and accessible solution provides a robust solution for the genetics professionals' community.

"We are delighted to have partnered with FDNA. FDNA's unique technology, innovative solutions and strong commitment to the community of genetics professionals made them a perfect partner to carry our life's work of curation into the new era of dysmorphology," said Dr. Michael Baraitser, Co-Author of LMD. "Making LMD available online is a long awaited need. FDNA's innovative technology adds unparalleled value to our existing and new customers. This unique combination allows users to access the most updated LMD version anytime, anywhere and easily search for the most relevant references," added Dr. Baraitser.

LMD has become, over the past 20 years, the gold-standard dysmorphology reference for genetics professionals. The databases include a superb collection of over 20,000 images, which show dysmorphic features and other relevant medical images associated with a multitude of genetic disorders.

"Integrating LMD into Face2Gene combines the world's first and only available computer-aided dysmorphology analysis solution with the most reputable dysmorphology database collection. The partnership places unparalleled power and convenience in the hands of thousands of medical professionals," said Dekel Gelbman, CEO of FDNA Inc. "We are honored to partner with LMD. This partnership further underscores our commitment to the genetics community. We plan to continue enhancing Face2Gene in many ways, making it better and more useful," added Mr. Gelbman.

Under this partnership, Dr. Baraitser will join FDNA's scientific advisory board headed by Dr. Michael R. Hayden and comprised of some of key opinion leaders in genetics, Including Dr. David A. Chitayat, Prof. Jill Clayton-Smith, Dr. Cynthia J.R. Curry, Prof. Dian Donnai, Dr. Sofia Douzgou, Dr. Karen W. Gripp, Dr. Judith G. Hall, Prof. Arnold Munnich, Prof. Motti Shohat, and Prof. Lina Vanagaite-Basel.

About LMD:

Co-founded by Prof. Robin Winters and Dr. Michael Baraitser and edited by both until the premature death of Prof. Winter in 2003, LMD produces award-winning databases in the medical genetics field. With a worldwide user base built up over 20 years and drawing on the extensive clinical experience of their authors, the databases have become invaluable reference and diagnostic tools for the clinician. Currently the LMD series comprises: Winter-Baraitser Dysmorphology Database (WBDD), Baraitser-Winter Neurogenetics Database (BWDB) and London Ophthalmic Genetics Database (GENEEYE).  

About FDNA:

Face2Gene is a genetic search and reference solution powered by FDNA® (Facial Dysmorphology Novel Analysis) technology. Face2Gene facilitates detection of facial dysmorphic features and recognizable patterns of human malformations to present comprehensive and up-to-date genetic references. Face2Gene aids and empowers in accelerating and increasing confidence in the research and investigation of genetic syndromes. The solution leverages advanced algorithms and the cumulative experience of hundreds of genetics professionals and tens of thousands of analyzed cases. Face2Gene technology improves over time, referencing comprehensive phenotype databases in real-time.

Contact: FDNA Inc.
Yaron Front, V.P. Marketing
+1-(347)-305-0076
yaron.front@fdna.com

SOURCE FDNA Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here